Maneuvering the Complex Web of Treatment Options for Relapsed/Refractory Multiple Myeloma
Clinicians face a difficult task of deciding who to treat, when to treat, and how to treat especially since many factors need to considered when determining the optimal multiple myeloma (MM) treatment for relapsed/refractory MM including: age, prognostic factors, comorbidities, toxicity profiles, response to prior therapy, previous relapses, availability of resources, and patient preferences. Therefore, an understanding of available therapies, how to sequence them and select the most appropriate choice is extremely important in improving patient outcomes. Often the best management of any patient is enrollment in a well-designed clinical trial. Clinicians need to be fully apprised of current trials and the benefits to patients to encourage clinical trial participation.
This activity is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, physician assistants, and other health care professionals who manage patients with hematologic malignancies.
Following this program, participants should be able to:
- Choose appropriate sequence of therapy for relapsed/refractory multiple myeloma (MM), taking individual patient characteristics into consideration.
- Discuss supportive care measures needed for patients with relapsed/refractory MM and outline strategies to manage them.
- Review emerging treatment options and employ effective communication strategies that will help convey the benefits and risks of clinical trial participation to patients.
Natalie S. Callander, MD
University of Wisconsin Carbone Cancer Center
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
The faculty listed below has no relevant financial relationships with ineligible companies to disclose.
Natalie S. Callander, MD
The faculty listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Muhamed Baljevic, MD
Amgen Inc.: Grant/Research Support
Aptitude Health: Honoraria
Atheneum: Consulting Fee
BMS/Celgene Corporation: Consulting Fee; Scientific Advisor
Bristol-Myers Squibb Company: Scientific Advisor
Cardinal Health Specialty Solutions: Scientific Advisor
Cardinal Health Specialty Solutions Oncology: Honoraria
Adaptive Biotechnologies: Honoraria
Coleman Research Group, Inc.: Consulting Fee
Exelixis Inc.: Grant/Research Support
Gerson Lehrman Group, Inc.: Consulting Fee
Guidepoint Global, LLC.: Consulting Fee
Janssen Research & Development, LLC.: Scientific Advisor
Karyopharm Therapeutics: Honoraria; Scientific Advisor
Oncopeptides: Scientific Advisor
Putnam Associates: Consulting Fee
Takeda Pharmaceuticals North America, Inc.: Consulting Fee; Scientific Advisor
NCCN Staff Disclosures
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 0.75 contact hour.
NCCN designates this knowledge-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-21-120-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit. Approval is valid until December 15, 2022. PAs should only claim credit commensurate with the extent of their participation.
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing